NCT07075224View on ClinicalTrials.gov

Pharmacodynamics of a Fixed Dose Combination of 0.34% Tropicamide and 2.5% Phenylephrine Hydrochloride, Eye Drop, Solution

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 15, 2025

Primary Completion Date

September 27, 2025

Study Completion Date

September 30, 2025

Conditions
Mydriasis
Interventions
DRUG

IMP 08P2002F0

Fixed combination of 0.34 % tropicamide and 2.5 % phenylephrine Hydrochloride (HCl) Eye drop Solution.

DRUG

Mydriasert® insert

0.28 mg tropicamide and 5.4 mg phenylephrine hydrochloride

Trial Locations (2)

10672

Ophthalmiatreion Athinon, Athens

41000

Iaso Thessalia General Clinic Private Obstetrics S.A., Larissa

All Listed Sponsors
lead

Unither Pharmaceuticals, France

INDUSTRY